Archive | Biopharmaceuticals

Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN

Lyrica no prescription Biotechnology Sector Continues Amazing Bull Run Up 40% YTD The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (BIIB) and Gilead Sciences (GILD) and with our bellwether ETF (IBB) eking out a 0.5% gain at its 52 week high. Since the bull market began in February 2009 several stocks […]

Continue Reading 0

Who Knows About the Bull Market in Biotech Stocks?

http://lesmasphotos.com/wedding-photography-for-delna-benjamin/bdweb-116/?share=facebook Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip stocks”; the other from an astute investor telling a […]

Continue Reading 0

NASDAQ Slips Down 0.4% But Biotech Sector Hits New Highs

enter site The ETF IBB (142.62) hit an all time high today and is up 36.6% YTD. The low for IBB over two years was August 19, 2011 at $88.50. Our mid-cap biopharma index is up 0.8% with big winners in JAZZ ($54.65) and Exelixis (EXEL $5.40) and Medivation (MDVN $106.27). Diagnostics and tools got some M&A […]

Continue Reading 0

Biotechnology Does Create Jobs and MASS Effort pays Off

The MASS Biotechnology industry has crossed $6B as a 25 year effort beginning in 1985 with the MASS Biotechnology Council. Several major biotechnology companies were created around this time such as Biogen(BIIB)  and Vertex (VRTX) as well as major venture capital firms who invested $1B in 2011 and $8B since 2002. Several major pharmaceutical firms […]

Continue Reading 0

You Know Its a Bull Market in Biotech When……Update 1 9/8/12

Valuations Don’t Matter-Institutional Holders Are the Drivers Medivation (MDVN $105.65) sold off 3 pts Friday on modest volume today as profit taking ensued after the big run-up from the high 95. With a market cap of $3.89B the sales of the FDA approved drug XTANDI are expected to begin in early 2013. But with institutions […]

Continue Reading 0

Rayno Biopharmaceutical Portfolio: ASTX IMGN, PCYC

ImmunoGen Gets Boost on Breast Cancer Drug Survival Results Immunogen (IMGN $14.36) and Roche announced improved overall survival (OS) as well as progression free survival (PFS) in a Phase III trial for its trastuzumab emtansine (T-DM1) drug utilizing Targeted Antibody Payload Technology ( TAP). The trastuzumab (Herceptin) antibody drug conjugate  is being developed jointly by […]

Continue Reading 0

Biotech Stocks Stall in Today’s Rally: Idenix Falls 29% Update 1 Aug 17

QQQs Outperforming Biotech ETFs IBB and XBI-Take a Little Off Biotech Stocks are weak again today with both ETFs showing distribution and momentum moving toward the bottom of the channel. Nothing major but 3-5% off July tops. The QQQs continue to outperform today up 0.21%. Large cap biotech losers are Alexion (ALXN $102.6), Biogen-Idec (BIIB […]

Continue Reading 0

Rayno Life Science Portfolio Notes: CPHD PCYC TMO

Biotechnology Sector Hit with Profit Taking This week’s Barrons: The West Coast Was the Right Coast Wedbush ranked #1 in % change 6 mo (+12.75%), one year (+18.84%) and three year (81.05%) stock picks and Seattle’s McAdams Wright Ragen scored #1 (+14.1%) in % change over  5 years. Wedbush and Rayno Life Sciences are in […]

Continue Reading 0

Biotech Stocks Fly Over Macro Flack: ALXN, ILMN, REGN, TMO

Rayno Life Science Focus Stocks Are Strong-TMO Added Biopharmaceutical stocks continue their run today beginning with higher sales expectations for Regeneron(REGN $128) with their eye drug for macular degeneration.Regeneron raised expectation for Eyelea to $700-750 from $500-550.Total revenue for Q2 was $304.4 with a profit up to $76.7M or 70 cents a share. The stock […]

Continue Reading 0

Clinical Diagnostics Stocks Sell-Off on Cepheid (CPHD $33.25) Guidance Cut

AACC  Meeting Hangover Begins With Cepheid Earnings Cuts–Stock Off 24% on Volume of 7M shares Cepheid (CPHD) a leader in molecular diagnostics, forecasted earnings of 38-42 cents a share for the year down from  50-55 cents a share on expected revenues in the range of $333-347M. Revenue for Q2 was $81M an increase of 21% […]

Continue Reading 0